Does bronchoalveolar lavage lymphocytosis predict prognosis in fibrotic hypersensitivity pneumonitis, and is this relationship influenced by low-dose immunomodulatory therapy at the time of BAL? - Poll - MDSpire

Can Lymphocytosis Detected in Bronchoalveolar Lavage Serve as a Prognostic Indicator in Fibrotic Hypersensitivity Pneumonitis, and Does Low-Dose Immunomodulatory Therapy Affect This Correlation?

  • By

  • Punchalee Kaenmuang

  • Fiammetta Danzo

  • Simon Bax

  • Richard J. Hewitt

  • Maria Kokosi

  • Vasileios Kouranos

  • Felix Chua

  • Peter M. George

  • Gisli Jenkins

  • Athol U. Wells

  • Carmel J. W. Stock

  • Piersante Sestini

  • Elisabetta A. Renzoni

  • July 21, 2026

Share

Original Source(s)

Does bronchoalveolar lavage lymphocytosis predict prognosis in fibrotic hypersensitivity pneumonitis, and is this relationship influenced by low-dose immunomodulatory therapy at the time of BAL?

  • by Punchalee Kaenmuang, Fiammetta Danzo, Simon Bax, Richard J. Hewitt, Maria Kokosi, Vasileios Kouranos, Felix Chua, Peter M. George, Gisli Jenkins, Athol U. Wells, Carmel J. W. Stock, Piersante Sestini, Elisabetta A. Renzoni

  • July 21, 2026

Related Content

Acupuncture for Neuroinfections?

A recent Perspective offered a speculative mechanistic argument for acupuncture’s potential role as an adjunctive strategy in neuroinfectious diseases.

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

The importance of robust genomic testing for patients

Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.

  • June 25, 2026

  • 1 min